Immunowake
Immunowake is a pre-clinical stage company dedicated to developing bi-specific antibodies for cancer therapy. Their mission is to awaken the patient’s immune system to recognize and kill cancer cells, aiming to create safer and more effective immunotherapies. They focus on innovative platforms such as the CD3 Bi-specific Platform and VEGF Trap Platform, with a strategic goal to develop next-generation bi-specific antibodies that overcome current limitations in cancer immunotherapy.
Industries
Nr. of Employees
small (1-50)
Patents
Products
CD3-targeting bispecific antibody platform
A bispecific antibody platform that engages CD3 on T cells and tumor-associated antigens using low-affinity CD3 binding within an IgG-like format to favor antigen-dependent activation and improved pharmacokinetics.
Checkpoint inhibitor + VEGF trap fusion platform
A bifunctional fusion protein approach combining immune checkpoint binding domains with VEGF-trapping domains fused to antibody chains to simultaneously block checkpoint pathways and neutralize angiogenic signals.
In vitro cell-based screening system
Cell-based assay systems for rapid screening of bispecific antibody biological activity and for discovery of new surface antigens amenable to immunotherapy.
CD3-targeting bispecific antibody platform
A bispecific antibody platform that engages CD3 on T cells and tumor-associated antigens using low-affinity CD3 binding within an IgG-like format to favor antigen-dependent activation and improved pharmacokinetics.
Checkpoint inhibitor + VEGF trap fusion platform
A bifunctional fusion protein approach combining immune checkpoint binding domains with VEGF-trapping domains fused to antibody chains to simultaneously block checkpoint pathways and neutralize angiogenic signals.
In vitro cell-based screening system
Cell-based assay systems for rapid screening of bispecific antibody biological activity and for discovery of new surface antigens amenable to immunotherapy.
Services
Using modular bispecific platforms to design and generate bispecific antibody candidates for preclinical evaluation.
Design and preclinical evaluation of checkpoint inhibitor–trap fusion proteins that neutralize soluble immunosuppressive or pro-angiogenic ligands.
Cell-based assay platforms to screen biological activity and effector functions of multispecific antibodies and to identify cell-surface targets.
Using modular bispecific platforms to design and generate bispecific antibody candidates for preclinical evaluation.
Design and preclinical evaluation of checkpoint inhibitor–trap fusion proteins that neutralize soluble immunosuppressive or pro-angiogenic ligands.
Cell-based assay platforms to screen biological activity and effector functions of multispecific antibodies and to identify cell-surface targets.
Expertise Areas
- Bispecific antibody development
- Fc engineering and pharmacokinetic optimization
- Fusion protein 'trap' therapeutics
- High-throughput cell-based assay development
Key Technologies
- IgG-like bispecific antibody formats
- Fusion protein trap design (ligand sequestration)
- Low-affinity CD3 engagement strategies
- Modular Fab-swapping platforms
News & Updates
Immunowake raised $20M in pre-series A financing led by Hyfinity Investments, with additional investors including South China Venture, Lapam Capital, and HEDA Ventures. The funds will be used to accelerate cytokine pipeline development and clinical trials.
Immunowake entered into licensing agreements with Genescience Pharmaceuticals Co., Ltd and Genscript Biotech Corp to obtain exclusive licenses to PD-L1 antibodies for multi-target therapeutics development.
Immunowake raised $3M in financing led by Changchun High-tech Industries Group Inc to accelerate research, development, and commercialization.
Immunowake raised $20M in pre-series A financing led by Hyfinity Investments, with additional investors including South China Venture, Lapam Capital, and HEDA Ventures. The funds will be used to accelerate cytokine pipeline development and clinical trials.
Immunowake entered into licensing agreements with Genescience Pharmaceuticals Co., Ltd and Genscript Biotech Corp to obtain exclusive licenses to PD-L1 antibodies for multi-target therapeutics development.
Immunowake raised $3M in financing led by Changchun High-tech Industries Group Inc to accelerate research, development, and commercialization.